These hub genes —key regulators of cytoskeletal dynamics and cell migration—implies that LSM2 may promote glioma progression by dysregulating these effector molecules, potentially via aberrant splicing of their pre-mRNAs. Here, LSM2 is linked to central nervous system cancer.